▟ Vinebot intrinsic value, daily

← back

PFE Pfizer

pharma · valued with opus medium conviction · deep-dived 2026-10-22

HOLD
Intrinsic value$15.11
Price (at call)$29.85
Margin of safety -49.4%
vs market (rating basis) -18.9%

Patent-cliff pharma priced for margin repair; fair only if cost cuts and oncology fully offset LOEs.

The story

Pfizer is a scaled, cash-generative big pharma that has worked through its COVID revenue collapse and now faces a 2026-2028 patent cliff (Eliquis, Ibrance, Xtandi and others, roughly $17B of revenue at risk). Seagen oncology, the vaccines franchise, Metsera obesity assets and about $7B+ of cost cuts are meant to offset that. It is a mature, ex-growth franchise. Its moat is R&D scale, distribution and a deal-making balance sheet, and that balance sheet is now stretched by about $63B of net debt. Value depends on restoring margins while revenue stays roughly flat, not on growth.

Growth and reinvestment are kept from last time because the patent-cliff facts have not changed. I raised the target margin from 25% to 28% because GAAP EBIT is weighed down by roughly $5B+ of acquisition amortization and IPR&D, while cash-based margins already run in the low 30s. I raised beta from 0.65 to 0.75 to move it toward the 0.95 industry anchor given the heavy leverage. Together these address the prior take's implied >100% gap to the market.

Value drivers

Revenue growth (Y1)-4.0%
Terminal growth2.2%
Forecast horizon8y
Target operating margin28.0%
Years to target margin6
Sales-to-capital1.20
Beta0.75
Failure probability2.0%
Cost of capital (WACC)9.2%
Terminal WACC10.1%

Valuation bridge

PV of explicit FCFF67.99B
PV of terminal value83.02B
Equity value86.13B
÷ shares → per share$15.11

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 61.15B -4.0% 13.7% 8.38B 0 8.38B 7.67B
2 59.24B -3.1% 16.6% 9.81B 0 9.81B 8.22B
3 57.92B -2.2% 19.4% 11.25B 0 11.25B 8.63B
4 57.14B -1.3% 22.3% 12.73B 0 12.73B 8.94B
5 56.88B -0.5% 25.1% 14.30B 0 14.30B 9.19B
6 57.13B 0.4% 28.0% 16.00B 203.16M 15.79B 9.29B
7 57.88B 1.3% 28.0% 16.21B 625.68M 15.58B 8.39B
8 59.15B 2.2% 28.0% 16.56B 1.06B 15.50B 7.64B

Key risks

  • Patent-cliff erosion (Eliquis, Ibrance, Xtandi) outruns launches and cost cuts
  • Seagen/Metsera pipeline disappointments forcing further write-downs or costly M&A
  • Net debt of about $63B limits flexibility and squeezes the dividend if cash flow slips
  • US drug pricing pressure (IRA negotiation, MFN policies)

Catalysts

  • Execution on cost cuts lifting operating margin toward the high 20s
  • Positive late-stage oncology ADC or obesity readouts
  • Deleveraging that restores M&A and buyback capacity

History

DatePriceIntrinsicMoSRating
2026-10-22$29.85 $15.11 -49.4% HOLD
2026-09-18$27.64 $12.83 -53.6% HOLD
2026-08-18$26.87 $0.00 -100.0% STRONG SELL
2026-07-15$24.25 $16.75 -30.9% BUY
2026-06-23$24.72 $17.72 -28.3% BUY